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P < 0.05) among fully vaccinated children (n = 101) when compared to unvaccinated 
children (n = 141). Secondly, there was no signiﬁ cant reduction in ILI and visits to 
physician among partially vaccinated children (n = 52) versus unvaccinated children 
(OR 1.54 [0.77–3.07], P = 0.24 and OR 1.81 [0.65–5.27], P = 0.30) respectively. 
CONCLUSIONS: Based upon these ﬁ ndings, it is concluded that seasonal inﬂ uenza 
vaccine is effective in reducing the ILI and visits to physician for ARI among fully 
vaccinated Indian children. Partially vaccinated children had no statistically signiﬁ cant 
protection against ILI and visits to physician. To the best of our knowledge, this is 
the ﬁ rst report on the clinical effectiveness of seasonal inﬂ uenza vaccine in healthy 
Indian children. 
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OBJECTIVES: To assess the efﬁ cacy and safety of raltegravir (integrase strand transfer 
inhibitor) compared to non-nucleoside reverse transcriptase inhibitors (nevirapine, 
efavirenz) and protease inhibitors (lopinavir, atazanavir) in treatment-naive patients 
with HIV infection. METHODS: A systematic literature search identiﬁ ed seven treat-
ment naïve trials comparing raltegravir to other treatments of interest via the common 
comparator efavirenz. This network of evidence was analyzed using a Mixed Treat-
ment Comparison (MTC). Selected outcomes were the proportion of patients with 
plasma HIV RNA less than 50 copies per mL at 48 weeks (efﬁ cacy) and discontinu-
ations (safety). A Bayesian approach was chosen and implemented in WinBugs. Fixed-
effect and random-effect models were run and the most appropriate model was 
selected based on the performance of the Monte Carlo simulations and the Deviance 
Information Criterion. Results were reported as median odds ratio, relative risk, and 
risk difference of raltegravir versus each comparator and associated 95% credible 
intervals. Bayesian inference also allows for treatment to be ranked, by calculating the 
proportion of simulations in which this treatment performs “best” in terms of relative 
efﬁ cacy/safety. RESULTS: For both efﬁ cacy and safety outcomes the ﬁ xed-effect 
models were preferred. Efﬁ cacy results showed a signiﬁ cant advantage of raltegravir 
compared to atazanavir, lopinavir, and nevirapine. Raltegravir also performed numeri-
cally better than efavirenz, and overall had a 71% probability of being the more efﬁ ca-
cious treatment on this outcome. Safety results also favored Raltegravir, but 
signiﬁ cance was only reached compared to nevirapine. CONCLUSIONS: The MTC 
suggests that raltegravir has an advantage that is at least numerical and in some cases 
statistically signiﬁ cant over its comparators in term of achieving plasma HIV less than 
50 copies per mL and avoiding discontinuation, providing additional data that sup-
ports the use of raltegravir in this indication. 
PIN10
A SYSTEMATIC REVIEW OF THE ATTRIBUTION OF HUMAN 
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OBJECTIVES: Estimating vaccine effectiveness is crucial for policymakers. Human 
Papillomavirus (HPV) type-speciﬁ c attribution to cervical cancers and precancers is 
one key factor in this regard for HPV vaccination and cancer screening. Among a 
number of reports on HPV type prevalence, only a few investigated attributions 
considering multitype infections and sampling methods. The objective of this study 
was to elucidate HPV type-speciﬁ c attribution in Japanese women. METHODS: A 
systematic review of published studies was conducted. Sampling methods were divided 
into two categories: one group consists of studies where HPV DNA was extracted 
from exfoliated cells, and another group consists of those using tissue specimens 
obtained by biopsy or surgical resection. To elucidate interrelationships among mul-
tiple HPV types in contributing to lesion development, attribution of each HPV was 
estimated assuming a fractional allocation of multitype infection. RESULTS: The 
overall positivity for any HPV was consistently higher in the exfoliated-cell group. On 
the other hand, attribution of HPV types 16 and 18 to cervical lesions was nominally 
higher in the tissue-specimen group. Attribution of HPV types 16 and 18 to cervical 
squamous cell carcinoma (SCC) was estimated as 47.4% (95% CI: 43.8–51.1) and 
9.4% (7.5–11.7) in the tissue-specimen group and 43.3% (38.5–48.2) and 7.6% 
(5.4–10.6) in the exfoliated-cell group, respectively. CONCLUSIONS: HPV positivity 
was higher in the exfoliated-cell group while type 16/18 attribution was nominally 
higher in the tissue-specimen group. Attribution of HPV type 16 to SCCs and adeno-
carcinomas (AC) derived from tissue specimens, after adjustment for multitype infec-
tions, was ~20% lower in Japanese women compared to data previously reported for 
US women. Type 18 attribution in Japanese women was similar to the United States 
for SCC and 10% lower for AC. 
INFECTION – Cost Studies
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OBJECTIVES: GPO-VIR® S (Stavudine, Lamivudine, Navirapine) has been used in 
people living with HIV/AIDS in Thailand since 2002. Drug resistance and adverse 
drug events (ADEs) are likely to be found. To solve this problem, GPO-VIR® Z 
(Zidovudine, Lamivudine, Navirapine) has been developed since 2005. Therefore, this 
study was conducted to evaluate the cost of ADEs found in people living with HIV/
AIDS receiving GPO-vir® S compared with GPO-vir® Z. METHODS: A retrospective 
cohort study design was used to determine the ADE costs of GPO-vir® S and GPO-vir® 
Z based on provider’s perspective. Direct medical costs (i.e., drug, laboratory, hospi-
talization, administration etc. ) were directly collected from patient proﬁ les from 
March 2005 to May 2008 at Nakornping hospital, Chiangmai province, Thailand. 
Total cost and average cost per ADE were calculated. RESULTS: A total of 136 
patients were studied. Of those, 95 cases received GPO-vir® S and 41 cases received 
GPO-vir® Z. Total ADEs found were 57 and 14 in GPO-vir® S and GPO-vir® Z groups 
respectively. Lipodystrophy (52.6%) was mostly found in GPO-vir® S group while 
anemia (28.7%) was found in GPO-vir® Z group. The total cost was 923,971 baht 
and 65,594 baht in GPO-vir® S and GPO-vir® Z respectively. An average cost per 
event in GPO-vir® S group was 16,210 baht and GPO-vir® Z group was 4686 baht. 
CONCLUSIONS: Although treatment with GPO-vir®Z seems to present lower costs 
of ADEs, selection of drug regimen still need to depend on the symptoms of individual 
patient. 
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OBJECTIVES: To quantify the ﬁ nancial burden of chronic hepatitis B (CHB) infection 
and its complications in a cost-of-illness study in Vietnam, a highly endemic country 
of hepatitis B virus (HBV) infection. METHODS: The study adopted the micro-costing 
approach. For direct medical cost estimation, data were retrieved retrospectively from 
medical histories of inpatients and outpatients with various CHB infection stages in 
2008 from a large referral hospital in Vietnam. For direct nonmedical and indirect 
cost estimation, data were obtained from outpatients from the same hospital through 
face-to-face interviews. One- and two-way analyses were performed on the cost cal-
culated. RESULTS: In 2008, the total cost of CHB infection and its complications 
was estimated to be around US$ 10 billion, with 80% contributable to direct medical 
cost. Antivirals were the major cost driver in treating CHB infections. The per-patient 
total annual direct medical cost increased with the severity of the disease with the cost 
amounted to US$ 943.64 for CHB and US$ 3916.21 for hepatocellular carcinoma. 
Based on the results, if all Vietnamese patients received treatment for CHB infections, 
the estimated cost would be twice as much as the total health budget of Vietnam, 
highlighting that a signiﬁ cant proportion of CHB infections in Vietnam are not being 
treated, and the patients are bearing the extra cost out-of-pocket, or seeking treatment 
from traditional medicines. CONCLUSIONS: This study conﬁ rms that chronic HBV 
infection poses an unbearable ﬁ nancial burden for the average patient with a GDP per 
capita of around $1024, and the lack of access to treatment is a social issue in Vietnam. 
Although universal newborns vaccination against HBV has been implemented to 
reduce the number of infected subjects, more health-care investment to improve access 
and provision of affordable medications by re-examining pharmaceutical policies to 
attain equity in proper treatment for patients with CHB infections would be needed. 
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OBJECTIVES: 1) Assess the proportion of anogenital warts to the total number of 
Sexual Transmitted Infection (STI); and 2) Quantify the direct medical costs of ano-
genital warts from patient perspective. METHODS: A prospective observational study 
was conducted in STI Clinic at Bangrak Hospital, Bangkok, Thailand from June 
2008–September 2009. The proportion of anogenital warts to the total number of STI 
was calculated from the database of Bangrak Hospital. A total of 131 patients with 
clinically diagnosed anogenital warts were recruited. After baseline assessment, the 
patients had three additional follow-up-visits at day 7, month 1, and month 3. On 
each visit, patients were examined and interviewed for health-care costs, work pro-
ductivity loss and activities impairment. At month 6, telephone assessment for the 
signs of disease recurrence was done. Patients were treated according to standard 
medical practice. RESULTS: The proportion of anogenital warts to the total number 
of STI in 2008 was 14.6%. The mean age (SD) of the study subjects was 28.2 years 
(7.4 years). Males and females were approximately equal (males 51.9%, female 
48.1%). Most of them were employed (51.1%), the rest were sex workers (25.2%), 
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and students (18.3%). The majority (83.2%) were treated with podophyllin paints. 
At 6 months, 55.0% were cured, 25.2% still had ongoing genital warts, 5.7% had a 
recurrence, 12.2% were lost to follow-up and 1.5% was discontinued. The median 
direct medical costs were 998 (range 130–4060) Thai Baht. All patients were treated 
as out-patient cases and 71.7% came to hospital without work absenteeism. After 
having genital warts lesion, work productivity was reduced to 83.0% (17.3) and daily 
activity was also declined to 82.4% (14.4) from baseline. CONCLUSIONS: Anogeni-
tal warts are common STI and tend to be recalcitrant to treatment. They also lead to 
the reduction on work productivity and daily activity. 
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OBJECTIVES: In Korea, rotavirus gastroenteritis rarely causes mortality, but it causes 
signiﬁ cant morbidity among young children. The objective of this study was to estimate 
the public health burden and the potential impact of universal vaccination with a three-
dose pentavalent rotavirus vaccine in Korea. METHODS: A Markov cohort simulation 
model was developed to project the expected clinical burden of rotavirus gastroenteritis 
and the potential impact of universal vaccination (vs.no vaccination) if all children are 
given a three-dose pentavalent rotavirus vaccine for the 2007 birth cohort of 493,189 
Korean infants during the ﬁ rst 5 years of life. Vaccine efﬁ cacy for preventing rotavirus 
and the associated use of health-care resources was based on the Rotavirus Efﬁ cacy and 
Safety Trial (REST) results. Data on rotavirus related health-care resource utilization 
were based on published sources. Data on the cost of treating rotavirus diarrhea were 
extracted from a hospital cost survey and the National Health Insurance claims data. 
One-way sensitivity analysis was conducted by varying the health-care resource utiliza-
tion and the discount rate from 3% to 7%. RESULTS: The three-dose rotavirus vaccina-
tion program would result in the prevention of 181,238 symptomatic cases (reduction 
rate: 63.2%), 27,200 hospital admissions (90.8%), 7602 emergency department visits 
(86.5%), and 538,399 outpatient visits (76.7%) during the 5 years after birth if all 
children are vaccinated. The break even price of vaccination was estimated to be between 
KW 50,454 and 61,667 per dose. CONCLUSIONS: Implementing a three-dose univer-
sal rotavirus vaccination strategy would likely result in a substantial reduction in 
rotavirus related health-care resource utilization in Korea. These results may be useful 
for evaluating rotavirus vaccination programs in Korea. 
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OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 
1-year peginterferon alfa-2a compared to 3 years entecavir for the treatment of 
HBeAg-positive chronic hepatitis B in China. METHODS: A Markov health-state 
model was designed to evaluate the direct medical costs and outcomes (life-years and 
QALYs gained) of treating HBeAg-positive chronic hepatitis B in China. The model 
included 10 health states—Chronic hepatitis B (CHB), HBeAg seroconversion, HBsAg 
loss, CHB with resistance, Compensated cirrhosis, Decompensated cirrhosis, Hepato-
cellular carcinoma, Liver transplant, Post-liver transplant and death. The model incor-
porates a maximum analysis time horizon of 80 years with yearly cycles. The clinical 
and quality of life data were obtained from published literature and re-conﬁ rmed 
based on a questionnaire survey from a clinical expert panel of 20 hepatitis B special-
ists. From the perspective of China’s health insurance system, cost data was calculated 
based on the published literature about economic burden of chronic hepatitis B. A 
discounting rate at 3% was used to discount medical costs happened at different years. 
A univariate sensitivity analysis was performed to understand the key drivers and 
general sensitivity of the model. RESULTS: The model results showed that the utiliza-
tion of 1-year peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 
0.885 QALYs, compared to the 3 years entecavir treatment. The total cost per patient 
treated with peginterferon alfa-2a was CNY 151,770 (US$ 22,221), and CNY 
129,239 (US$ 18,922) for patient treated with entecavir. The discounted incremental 
cost per QALY gained for pegainterferon alfa-2a was CNY 25,452 (US$ 3,727). 
CONCLUSIONS: The results of the model suggest that 1 year pegainterferon alfa-2a 
improves health outcomes in a cost-effective manner compared with 3 years entecavir 
in the treatment of HBeAg-positive chronic hepatitis B in China. 
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OBJECTIVES: Several decision support tools have been developed to aid policy 
decision-making regarding the adoption of pneumococcal conjugate vaccine (PCV) 
into national immunization programs. Lacking critical evaluation of the tools causes 
decision-makers difﬁ culties in understanding and feeling ownership of information 
resulting from the tools, particularly in resource poor countries where technical capac-
ity is lacking. This study aims to critically compare decision-making tools and their 
cost-effectiveness (CE) ﬁ ndings, and to identify inﬂ uential parameters in the models. 
The overall objective is to provide decision makers with a menu of CE tools and their 
characteristics for their optimal use rather than to recommend a single model. 
METHODS: The WHO requested access to publicly available CE tools for PCV from 
both public and private provenance. All tools were assessed according to WHO’s 
economic evaluation guideline. All key attributes and characteristics were compared. 
A series of sensitivity analyses were performed to determine the major drivers of the 
models. The results were compared using a standardized set of input parameters. 
RESULTS: Three CE tools, including PAHO ProVac’s TriVac, PneumoADIP and 
GSK’s SUPREMES tools, were provided. They all compared the adoption of PCV into 
national immunization program with no immunization. The models differed in terms 
of attributes, structure, and data requirement, but captured similar range of diseases. 
Herd effect was estimated using different approaches. The main driving parameters 
were vaccine efﬁ cacy against pneumococcal pneumonia, vaccine price and coverage, 
serotype coverage and disease burden. With a standardized set of input parameters, 
TriVac and PneumoADIP provided similar ﬁ ndings including incremental costs, 
outcome and incremental cost-effectiveness ratio. CONCLUSIONS: Models differed 
in terms of model structure and key assumptions. Vaccine price and efﬁ cacy were the 
most inﬂ uential parameters. Understanding differences and similarities of CE tools 
could provide policymakers more efﬁ cient use for aiding their decision-making 
process. 
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OBJECTIVES: Cost-effectiveness studies using local health data have supported the 
long-term health and economic beneﬁ ts of the 7-valent pneumococcal conjugate 
vaccine (PCV-7) due to herd immunity, which also led to its inclusion in the routine 
immunization program for infants in Hong Kong in September 2009. The aim of the 
present study is to assess the clinical and economic impacts of the new PCV-13 vaccine 
on the whole population of Hong Kong compared to no vaccination. METHODS: A 
decision analytical model modiﬁ ed from the recent Prevenar 13Ò Economic Impact 
(PREVENT) Model (RTI Health SolutionÒ) was used for the analysis of the outcomes 
of vaccination. The whole population of Hong Kong of around 7 million was analyzed 
with infants ≤2 either vaccinated or not vaccinated with PCV-13. Population data, 
incidence rates, serotype coverage, disease sequelae, mortality rates, vaccine effective-
ness, duration of protection, herd effects, utilities, cost of vaccination, and other direct 
costs were adopted from local published studies, previous economic assessments of 
PCV-7/PCV-13 and local government sources to populate the model. Data were 
adopted from overseas published studies if local data was not available. Sensitivity 
analyses were performed to check the robustness of the results. The time horizon was 
one year and the study was performed from a public health-care organization perspec-
tive. RESULTS: Over 1 year, our analysis shows for a four-dose regimen of PCV-13: 
a gain of 17 quality-adjusted-life-years (QALY), an avoidance of 1281 related illnesses 
and two deaths. Cost/life-year gained was US-145,014 and cost/QALY was 
-US161,127. CONCLUSIONS: Based on the WHO recommended international 
thresholds for cost-effectiveness, with GDP per capita of Hong Kong being US29,902 
in 2009, our study results suggest PCV-13 vaccination is very cost-effective in provid-
ing protection to the people of Hong Kong from the perspective of a public health-care 
organization. 
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OBJECTIVES: To perform a cost-effectiveness analysis of universal newborn vaccina-
tion against hepatitis B virus (HBV) and to identify the affordability of the program 
in Viet Nam, a highly endemic country of HBV infection. METHODS: Marginal cost 
of every life-year and quality-adjusted life-year (QALY) gained with universal newborn 
vaccination against HBV was calculated using a Markov model. Two types of analyses 
(including and excluding expenditure on the treatment of chronic hepatitis B and its 
complications) were performed. We conducted one-way sensitivity analyses to conﬁ rm 
the robustness of the results. We used Monte Carlo simulations to examine the afford-
ability of the vaccination program from payer’s perspective to derive an affordability 
curve for the program. RESULTS: In the base-case scenario, universal newborn vac-
cination against HBV reduced the carrier rate by 72%, and increase number of life-
years and QALY gained of a 2008 birth cohort by 1.8 years (71.21 years vs. 69.41 
years) and 2.26 years (71.03 years vs. 68.77 years), respectively. Marginal cost per 
life-year and per QALY gained were US$ 18.82 and US$ 13.16, much lower than the 
annual GDP per capita of around US$1024). The probability of the vaccination 
program to be both cost-effective and affordable is 60% at an annual program cost 
of US$253,000 (from the payer’s perspective), where the threshold cost-effective value 
is US$ 13.16 per QALY gained. CONCLUSIONS: Universal newborn vaccination 
